CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers. A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A. Small molecule inhibitors targeting eIF4F display promising anti-neoplastic activity in preclinical settings. Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies. Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Generation and Characterization of a Rocaglate-Resistant eIF4A1 Allele (A) Schematic illustrating conserved motifs of the DEAD-box helicase family. Sequences of the conserved motifs are denoted with motifs involved in RNA binding highlighted in bold red. The structure of eIF4A indicates it to be dumbbell in shape with two domains (I and II) linked via a flexible linker sequence. The inset shows a ribbon diagram of eIF4A1 (PDB 2ZU6) aligned to eIF4A3 (not shown; PDB 2HYI). The residues targeted for mutagenesis are highlighted and the single-stranded RNA substrate (positioned relative to the eIF4A3 crystal structure) is shown in orange. (B) Coomassie stain of purified recombinant eIF4A1 proteins. (C) Assessment of ATP hydrolysis by recombinant proteins via thin layer chromatography. (D) Kinetics of ATP hydrolysis by eIF4A1 and eIF4A1(F163L). ATPase assays were performed with 1 µg protein and varying ATP concentrations. Graph represents the Michaelis-Menten fit from two independent experiments. (E) RNA binding activity of eIF4A1 and eIF4A1(F163L) using [32P]-labeled RNA generated from pSP/CAT (see Supplemental Experimental Procedures). Assays were performed in the presence of 0.5% DMSO or 1 µM silvestrol and the retained eIF4A:RNA complexes are set relative to DMSO controls. n = 3 biological replicates performed in triplicate ±SEM; *p < 0.001. (F) Quantitation of eIF4A1 and eIF4A1(F163L) helicase activity performed with 0.5 µg recombinant eIF4A1 and an 11-nt radiolabeled RNA duplex in the presence of DMSO or 50 µM silvestrol. n = 3 biological replicates ±SEM; *p < 0.05. (G) DSF analysis of eIF4A1 or eIF4A1(F163L) in the presence of DMSO or (−)-SDS-1-021.](https://figures.cochat.ai/paper-figures/9cb1c6f5d11940758545e8724b488b98/crispr-mediated-drug-target-validation-reveals-selective-pharmacological-figure-1.jpg)
![Figure 2 Ectopic Expression of eIF4A1(F163L) Confers Resistance to Rocaglates in Mammalian Cells (A) Schematic diagram of RCV designed to simultaneously express an shRNA-resistant His6-eIF4A1 allele while suppressing endogenous eIF4A1. (B) Representative western blot of NIH/3T3 cells transduced with RCVs. The dashed line separates the two sets of western blots. (C) Viability assay of RCV-transduced NIH/3T3 cells. Cells were exposed to the indicated concentrations of silvestrol and relative viability was assessed 6 days later by sulforhodamine B (SRB). n = 2 biological replicates performed in duplicates ±SEM. (D) Competition assay of transduced NIH/3T3 cells. Transduced cells (GFP+) were mixed with parental cells (GFP−) and cultured in the presence of 20 nM silvestrol. The percentage of GFP+ cells was determined on the indicated days. n = 2 biological replicates performed in triplicate ±SEM. (E) Cells expressing eIF4A1(F163L) are resistant to translation inhibition by silvestrol. Transduced cells were incubated with the indicated concentrations of silvestrol for 1 hr and labeled with [35S]-methionine/cysteine during the last 15 min. n = 4 biological replicates ±SEM. (F) Polysome profiles of transduced NIH/3T3 cells following exposure to 200 nM silvestrol for 30 min. P/M represents the polysome/monosome ratio. n = 3 biological replicates ±SEM. See also Figure S1.](https://figures.cochat.ai/paper-figures/59837e245dbd4f9fa49cb393ac9b55ee/crispr-mediated-drug-target-validation-reveals-selective-pharmacological-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CRISPR is significantly benefitting and improving immunotherapy89, organoid engineering and development90, in vivo drug target identification91, machine learning and artificial intelligence92, and disease-gene modification in viable human embryos32.”
From CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool (2019) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799 · cited 5×
“Strategies aimed at inhibiting eIF4F include blocking eIF4E:eIF4G and eIF4E-cap interaction, interfering with eIF4A1/2 activity, and suppressing eIF4E expression with antisense oligonucleotides (ASOs) (Bhat et al., 2015).”
BackgroundSelf-citationRNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635 · cited 4×
“…activity in a number of pre-clinical models (Bordeleau et al., 2008; Cencic et al., 2009; Wolfe et al., 2014), and are thought to exert their effects by preferentially inhibiting the translation of key oncogenic mRNAs (e.g., MYC) (Cencic et al., 2009; Rubio et al., 2014; Wolfe et al., 2014).”
BackgroundSelf-citationAntitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationRubio, C. A., Weisburd, B., Holderfield, M., Arias, C., Fang, E., DeRisi, J. L., & Fanidi, A. (2014) · Genome Biology · doi:10.1186/s13059-014-0476-1 · Cited by 200 · cited 1×
“…activity in a number of pre-clinical models (Bordeleau et al., 2008; Cencic et al., 2009; Wolfe et al., 2014), and are thought to exert their effects by preferentially inhibiting the translation of key oncogenic mRNAs (e.g., MYC) (Cencic et al., 2009; Rubio et al., 2014; Wolfe et al., 2014).”
BackgroundRodrigo, C. M., Cencic, R., Roche, S. P., Pelletier, J., & Porco, J. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201263k · Cited by 99 · cited 4×
“Since rocaglates increase the RNA binding of eIF4A and lead to its depletion from the eIF4F complex (Bordeleau et al., 2008; Rodrigo et al., 2012), wemonitored binding of eIF4A1 to (32)P-labeled RNA in vitro.”
BackgroundSelf-citationLeibiger, C., Kosyakova, N., Mkrtchyan, H., Glei, M., Trifonov, V., & Liehr, T. (2013) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413476868 · Cited by 92 · cited 1×
“These results are consistent with NIH/3T3 cells being tetraploid for chromosome 11 (the location of murine Eif4a1) (Leibiger et al., 2013).”
ResultTranslation initiation factor eIF4F modifies the dexamethasone response in multiple myeloma
Robert, F., Roman, W., Bramoullé, A., Fellmann, C., Roulston, A., Shustik, C., Porco, J. A., Shore, G. C., Sebag, M., & Pelletier, J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402650111 · Cited by 64
Self-citation
Research works printed but not linked: 19
- Bordeleau, 2008, Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model, J. Clin. Invest., 118, 2651
- Chu, 2016, Translation Inhibition by Rocaglates Is Independent of eIF4E Phosphorylation Status, Mol. Cancer Ther., 15, 136, 10.1158/1535-7163.MCT-15-0409 · DOI
- Elfakess, 2011, Unique translation initiation of mRNAs-containing TISU element, Nucleic Acids Res., 39, 7598, 10.1093/nar/gkr484 · DOI · Paper page
- Elliott, 1998, Gene conversion tracts from double-strand break repair in mammalian cells, Mol. Cell. Biol., 18, 93, 10.1128/MCB.18.1.93 · DOI · Paper page
- Galicia-Vázquez, 2012, A cellular response linking eIF4AI activity to eIF4AII transcription, RNA, 18, 1373, 10.1261/rna.033209.112 · DOI · Paper page
- Graff, 2007, Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity, J. Clin. Invest., 117, 2638, 10.1172/JCI32044 · DOI · Paper page
- Hong, 2011, A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer, Clin. Cancer Res., 17, 6582, 10.1158/1078-0432.CCR-11-0430 · DOI · Paper page
- Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc., 9, 2100, 10.1038/nprot.2014.138 · DOI · Paper page
- Lin, 2012, Targeting synthetic lethal interactions between Myc and the eIF4F complex impedes tumorigenesis, Cell Rep., 1, 325, 10.1016/j.celrep.2012.02.010 · DOI · Paper page
- Lorsch, 1998, The DEAD box protein eIF4A. 1. A minimal kinetic and thermodynamic framework reveals coupled binding of RNA and nucleotide, Biochemistry, 37, 2180, 10.1021/bi972430g · DOI · Paper page
- Niesen, 2007, The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability, Nat. Protoc., 2, 2212, 10.1038/nprot.2007.321 · DOI · Paper page
- Pan, 2014, Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species, Nat. Prod. Rep., 31, 924, 10.1039/C4NP00006D · DOI · Paper page
- Polier, 2012, The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2, Chem. Biol., 19, 1093, 10.1016/j.chembiol.2012.07.012 · DOI · Paper page
- Rajalingam, 2005, Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration, Nat. Cell Biol., 7, 837, 10.1038/ncb1283 · DOI · Paper page
- Sadlish, 2013, Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex, ACS Chem. Biol., 8, 1519, 10.1021/cb400158t · DOI · Paper page
- Smurnyy, 2014, DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells, Nat. Chem. Biol., 10, 623, 10.1038/nchembio.1550 · DOI
- Truitt, 2015, Differential requirements for eIF4E dose in normal development and cancer, Cell, 162, 59, 10.1016/j.cell.2015.05.049 · DOI · Paper page
- Yang, 2013, Optimization of scarless human stem cell genome editing, Nucleic Acids Res., 41, 9049, 10.1093/nar/gkt555 · DOI · Paper page
- Yoder-Hill, 1993, The p46 subunit of eukaryotic initiation factor (eIF)-4F exchanges with eIF-4A, J. Biol. Chem., 268, 5566, 10.1016/S0021-9258(18)53358-5 · DOI · Paper page
Cited by
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
Sensitization of renal carcinoma cells to TRAIL-induced apoptosis by rocaglamide and analogs
Nalli, A. D., Brown, L. E., Thomas, C. L., Sayers, T. J., Porco, J. A., & Henrich, C. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-35908-0 · Cited by 295
Self-citationTranslational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma
Cerezo, M., Guemiri, R., Druillennec, S., Girault, I., Malka-Mahieu, H., Shen, S., Allard, D., Martineau, S., Welsch, C., Agoussi, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0217-1 · Cited by 254
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150
eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma
Chan, K., Robert, F., Oertlin, C., Kapeller-Libermann, D., Avizonis, D., Gutierrez, J., Handly-Santana, A., Doubrovin, M., Park, J., Schoepfer, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13086-5 · Cited by 106
Self-citationMolecular Pathways: The eIF4F Translation Initiation Complex—New Opportunities for Cancer Treatment
Malka-Mahieu, H., Newman, M., Désaubry, L., Robert, C., & Vagner, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2362 · Cited by 105
“functional eIF4A1 allele that abolishes the cytotoxicity of flavaglines upon introduction into cells using the CRISPR/Cas9 technology suggests that eIF4A is the prime target of flavaglines in most of the cancers (35).”
MethodAmidino-Rocaglates: A Potent Class of eIF4A Inhibitors
Chu, J., Zhang, W., Cencic, R., Devine, W. G., Beglov, D., Henkel, T., Brown, L. E., Vajda, S., Porco, J. A., & Pelletier, J. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.08.008 · Cited by 74
“A rocaglate-resistant eIF4A1 mutant (F163L) has been characterized and introduction of this allele into cells using CRISPR/Cas9-mediated gene editing confers resistance to rocaglate cytotoxicity (Chu et al., 2016; Iwasaki et al., 2019), further demonstrating that the mechanism of action of these compounds is dependent…”
Self-citationThompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0973 · Cited by 50
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
“org Cancer Res; 81(8) April 15, 2021 2003”
BackgroundInfluentialZhao, N., Kabotyanski, E. B., Saltzman, A. B., Malovannaya, A., Yuan, X., Reineke, L. C., Lieu, N., Gao, Y., Pedroza, D. A., Calderon, S. J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci172503 · Cited by 30
Metadata
- Authors
- Chu, J., Galicia-Vázquez, G., Cencic, R., Mills, J. R., Katigbak, A., Porco, J. A., & Pelletier, J.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 15
- Issue
- 11
- Pages
- 2340-2347
- ISSN
- 2211-1247
- PMC
- PMC5315212
- Cited by
- 95
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.